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medications are only a palliation and not a cure for structural 
disadvantage 
 
Degeling C1, Johnson J, Mayes C. (2015) 
 
Caplan and colleagues (2015) present a strong argument for using alternative trial designs 
for experimental treatments for Ebola virus disease (EVD). This argument is, of course, not 
new.  There is a significant body of work in the philosophy of medicine which highlights the 
moral authority given to RCTs and the fact that RCTs are often chosen not because they are 
needed but because people simply do not recognise that they can get evidence that is just as 
useful from other trial designs (Kerridge 2010). 
 
The popularity of RCTs as a research methodology is supported by positivist assumptions 
that well-conducted RCTs permit experimenters to make strong causal claims and 
conclusions because this trial design uniquely controls for confounding factors.  RCTs do 
generally provide robust evidence, yet as the philosopher of science John Worrall (2007) 
demonstrates, randomisation, as a methodological principle, is not a sufficient condition to 
guarantee that the trial outcome will not be adversely influenced by uncontrolled or 
unknown factors. What this means is that RCTs are not necessarily epistemically secure or 
even always epistemically superior.  But, like other trial designs, the data generated by RCTs 
needs to be interpreted in light of other sources and forms of evidence. This raises concerns 
that the epistemic and moral authority accorded to RCTs can mandate inappropriate and 
ineffective interventions, and divert attention and resources away from other ways of 
addressing problems.  
 
RCTs are designed to establish the efficacy of interventions, not their effectiveness. Efficacy 
captures what happens in ideal circumstances – RCTs tell us what will happen in a 
population of patients given a treatment under specific sets of controlled conditions. RCTs 
do not necessarily provide a solid base for extrapolating or generalising what might happen 
when different types of individuals are given a treatment under different conditions 
(Cartwright 2011). For policy and practice – and especially at a time of pressing need – we do 
not need to know that one therapy works better than others (the standard of care (SOC) and 
/or other experimental agents) under specific sets of controlled conditions.  What we really 
need to know is that the intervention will be effective where it is needed most (Cartwright 
2011).  RCTs are not necessarily the “gold standard” but merely a standard trial design in 
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which important considerations such as affordability, sustainability and public acceptability 
remain unaddressed. This is undoubtedly relevant to arguments regarding the conduct of 
RCTs in West Africa as it suggests not only that randomisation of participants in drug trials in 
this setting is morally suspect because of the vulnerability of participants, the nature of the 
disease and the lack of capacity and resource scarcity of the setting – but also because 
assumptions about the epistemic and ethical benefits of RCTs are questionable; especially if 
the goal of the research is to choose the most effective therapy – the one that is most 
appropriate to the socio-cultural, economic and political conditions in which it is likely to be 
used.  
 
Caplan and colleagues (2015) are right to point out that, epistemologically speaking, RCTs 
are not needed and that sufficient evidence about the efficacy of new Ebola therapies can 
and should be obtained from other sources. However it is our contention that current 
debates about the scientific purity of different trial designs are a distraction from the goal of 
developing effective interventions for EVD.  This is because the purpose of this research [or 
the ‘job’ as described in the target article’s title] is not unproblematic and should be 
subjected to ethical scrutiny.  It is significant that arguments about different trial designs for 
potential Ebola therapies point to the importance of accommodating local conditions and 
resource settings.  Caplan and colleagues (2015) are careful to limit the frame of their 
inquiry to research ethics.  But if the social instability and resource scarcity of the setting 
where the drug trial is to be conducted are significant epistemic and ethical concerns, it is 
arguable that the underlying structural conditions should not be treated as a ‘natural state’ 
that policymakers and researchers must navigate. Rather, these structural conditions 
themselves warrant deeper consideration (Hooker et al. 2014).  
 
Infectious diseases such as Ebola, have, historically, been understood and approached in two 
ways: as matters of contamination and as matters of configuration (Rosenberg 1992). From 
the perspective of contamination – disease is the transfer and progress of infection between 
and within individuals.  In the case of the current Ebola outbreak, it seems that the index 
case was a two year-old boy infected from eating bush-meat (flying fox) sourced from a 
market in Guéckédou, in south-eastern Guinea. Yet even as contact exposure, host-
pathogen interactions and clinical interventions determine the disease state of individuals, 
these interactions take place in a social and material environment that can be configured in 
ways that enhance or inhibit the risk of infection and disease pathogenicity. Of this the field 
epidemiologists Daniel Bausch and Lara Schwarz (2014, e3056) note: 
 
Ebola virus outbreaks typically constitute yet another health and economic 
burden to Africa's most disadvantaged populations. … The effect of a stalled 
economy and government is 3-fold. First, poverty drives people to expand their 
range of activities to stay alive, plunging deeper into the forest to expand the 
geographic as well as species range of hunted game and to find wood to make 
charcoal and deeper into mines to extract minerals, enhancing their risk of 
exposure to Ebola virus and other zoonotic pathogens in these remote corners. 
Then, the situation is compounded when the unlucky infected person presents 
to an impoverished and neglected healthcare facility where a supply of gloves, 
clean needles, and disinfectants is not a given, leaving patients and healthcare 
workers alike vulnerable to nosocomial transmission. 
 
The cross-species transmissibility and spread of emerging infectious diseases such as EVD 
arises from changes in land use, and the intensification of trade, travel and/or animal 
husbandry practices (Wallace et al. 2014). The way that society is configured then exposes 
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specific populations to a higher or lower risk of infection and enables greater or lesser access 
to effective healthcare.  
 
Over the past 40 years many West Africa nations have undergone a process of ‘de-
development’. The implementation of structural-adjustment programs (SAPs) in exchange 
for World Bank and International Monetary Fund loans re-configured the conditions of 
infection (Jones 2011). While SAPs promised economic growth via global trade, they also led 
to the erosion of much of the local public infrastructure needed to prevent and control an 
infectious disease outbreak. Analyses of the unprecedented nature of the current outbreak 
EVD tend to focus on cultural burial practices or lack of drugs. Yet SAPs, civil war, political 
instability, corruption, neglect, mass refugee migrations and deforestation have 
undoubtedly played a decisive role in creating the conditions and amplifying the risks of 
infection (Bausch and Schwarz 2014).   
 
Despite significant re-configuration of the social and material environment, the 
contamination view of infectious disease dominates ethical thinking about responses to EVD 
- valorising individualised technological solutions and diverting attention away from the 
upstream socio-ecological causes and structural drivers of incidence. Drug trials for EVD that 
are not integrated with local measures which seek to address differences in people’s 
capacities, preferences, cultural commitments and socio-economic and environmental 
circumstances are ultimately more likely to produce ineffective interventions while also 
entrenching global health inequities.  
 
If the proposed solutions become ever more technological, isolationist and consumerist in 
orientation, then existing structures, systems and settings are increasingly likely to be seen 
as natural states, and, thereby, not amenable to reform.  The development of an effective 
therapy for EVD is only part of ‘the job’ that needs to be completed.  Prioritising studies that 
aim to test pharmaceutical efficacy rather than develop effective interventions that can be 
sourced and managed locally amounts to a program of research that further embeds then 
medicalizes the consequences of environmental degradation, poverty and structural 
disadvantage. Interventions being tested for outbreaks of infectious disease in the 
developing world need to be affordable, readily accessible by those who need them and 
appropriate to local conditions.  If Western interests continue to trump local interests we 
should ask: whose health is being prioritized; which public and which good are we seeking to 
protect? (Scoones and Forster 2009) 
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